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Abstract. – OBJECTIVE: The use of omalizum-
ab, a humanized monoclonal antibody able to bind-
ing Ig-E, is currently authorized only for treatment 
of severe bronchial asthma. The use of omalizum-
ab in other Ig-E related diseases is off-label, al-
though some studies have provided promising re-
sults about it. The aim of this study was to evaluate 
if therapy with omalizumab in patients affected by 
asthma and allergic rhinitis has an impact also on 
allergic rhinitis-related symptoms. 
PATIENTS AND METHODS: A longitudinal 
study was conducted on 11 patients affected by 
severe asthma and a periodic allergic rhinitis. Pa-
tients were treated with omalizumab for 24 weeks 
with a monthly subcutaneous administration at 
the dosage recommended by the current guide-
lines. We observed at the start and at the end of 
treatment: rhinitis symptoms using the Visual An-
alogue Scale (VAS); the state of nasal mucosa with 
fiberoptic nasal endoscopy; airways inflammation 
by measuring the Fractional Exhaled Nitric Oxide 
(FeNO); asthmatic symptomatology by means of 
the Asthma Control Test; the amount of total Ig-E 
in a blood sample; and the use of symptomatic 
drugs before and after treatment.   
RESULTS: VAS scores to measure general 
symptomatology and symptoms including na-
sal obstruction, rhinorrhea, itching and sneezing 
were significantly reduced. Turbinate hypertro-
phy was resolved in six of nine patients. Further-
more, eight patients (73%) reduced or eliminated 
the use of symptomatic drugs.  
CONCLUSIONS: Our data confirm the efficacy 
of omalizumab in the treatment of allergic rhini-
tis. Controlled studies will now have to be carried 
out to confirm these preliminary data and will 
specify indications for a very efficacious but still 
significantly expensive therapy.
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Introduction
Allergic rhinitis is a pathological condition of 
the nasal mucosa induced by an IgE-mediated in-
flammation following allergen exposure. Its inci-
dence is constantly increasing and prevalence in 
the world population reaches almost 30%1. Symp-
toms are characterized by rhinorrhea, sneezing, 
itching, nasal obstruction and tearing and may be 
reversed spontaneously or with drugs2. Its impact 
on quality of life is considerable as allergic rhini-
tis is an obstacle to social life; it reduces school 
and work performance and at the same time in-
volves significant costs for specific treatment.
Allergic rhinitis is often associated with bronchi-
al asthma. Over 50% of patients with rhinitis also 
suffer from asthma, and more than 80% of patients 
affected by asthma present concomitant rhinitis3. 
Often, the onset of rhinitis precedes the symptoms 
of asthma, although the factors responsible for the 
extension of disorders to the lower airways are still 
unknown. Moreover, usually the successful treat-
ment of rhinitis improves asthma symptoms, thus re-
ducing the frequency of exacerbations and hospital-
ization4,5. These epidemiological findings reinforce 
the assumption according to which allergic rhinitis 
and bronchial asthma are different components of 
the same IgE-mediated disease3. The convention-
al treatment of allergic rhinitis and allergy-related 
asthma is based on the removal of the responsible 
allergen, symptomatic treatment with nasal decon-
gestants, antihistaminics, topical corticosteroids and 
allergen-specific immunotherapy6,7. However, some 
patients are refractant to conventional therapies. 
Omalizumab is an anti Ig-E monoclonal anti-
body recently approved for the treatment of asth-
ma. It has proven to be very effective in improv-
ing the symptoms and reducing the number of 
exacerbations of this disease8. 
The aim of this study was to assess if treatment 
with omalizumab in a group of patients affected 
by asthma and concomitant allergic rhinitis also 
influenced the allergic rhinitis-related symptoms.
Patients and Methods
The patients included in the trial were recruited 
from the Rhinoallergology day hospital of the Oto-
rhinolaryngology Department of the “Sapienza” 
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University of Rome. Inclusion criteria were: a) di-
agnosis of a severe form of bronchial asthma with 
the indication for treatment with omalizumab es-
tablished by the Italian Drug Authority (AIFA); b) 
the concomitant presence of allergic rhinitis. The 
criteria for the prescription of omalizumab are: 
a) age over 12 years; b) persistent severe allergic 
asthma with skin tests or in vitro reactivity positive 
for a perennial aeroallergen; c) reduced pulmonary 
function (FEV1 <80%); d) frequent diurnal symp-
toms or nocturnal awakenings; e) repeated severe 
asthmatic exacerbations, despite the daily intake 
of high doses of inhalation corticosteroids plus 
an inhaled long-acting β2-agonist9. The diagnosis 
and evaluation of bronchial asthma severity were 
made in accordance with GINA guidelines10, and 
the diagnosis of allergic rhinitis according to the 
ARIA guidelines5. Patients who presented total se-
rum Ig-E not included between 30 and 1300 IU/
ml or body weight > 100 kg were excluded from 
the trial. The study protocol was approved by the 
Ethics Committee of the Sapienza University of 
Rome, and all enrolled patients gave their informed 
consent.
Omalizumab was administered every four 
weeks for 24 weeks for a total of 6 doses, in the 
form of pre-packaged subcutaneous injections, 
with a variable dose according to the weight of 
each patient and total serum Ig-E (Table I). The 
drug did not replace pharmacological therapy 
prescribed to patients for the treatment of rhinitis 
and concomitant asthma, but was added to it.
At the beginning of the trial (T
0
) and the end of 
treatment (T1) we evaluated:
  • General clinical conditions and intensity of 
individual symptoms (nasal obstruction, rhi-
norrhea, itching, sneezing, tearing) using the 
Visual Analogue Scale (VAS) with a score 
ranging from 1 (no symptom) to 10 (worst pos-
sible symptom)11. 
  • The state of nasal mucosa using fiberoptic na-
sal endoscopy.
  • The level of airways inflammation by measur-
ing Fractional exhaled Nitric Oxide (FeNO)12.
  • Asthmatic symptoms using the “Asthma Con-
trol Test” questionnaire13.
  • The level of bronchial obstruction with spi-
rometry (FEV1).
  • Eosinophil and the total IgE amount in a blood 
sample. 
Statistical Analysis
Values are reported as a median (range) or a 
number (percentage). Proportions were analyzed ac-
cording to Fisher’s exact test and quantitative vari-
ables were analyzed with Wilcoxon’s test. A value of 
p<0.05 was considered to be statistically significant.
Results
11 patients were included in the study (7 men 
and 4 women), aged between 26 and 70 years (mean 
47 years), with a weight between 60 kg and 100 kg 
(mean kg 77). All patients presented sneezing, nasal 
secretion, nasal obstruction and aqueous rhinorrhea. 
Following treatment with omalizumab, an improve-
ment of subjective symptomatology and clinical 
signs of the upper and lower airways was registered. 
The VAS score for the general clinical status was 
reduced significantly, with values decreased from 7 
(2-8) to 3 (2-5) (p=0.0125; Figure 1)
Considering allergic rhinitis, scores for individ-
ual symptoms (Table II) decreased in a statistical-
ly significant way in all cases except for tearing. 
At endoscopy, turbinate hypertrophy, which was 
initially reported in nine patients (81%), was ob-
served in only 3 patients (27%) after the treatment 
(p=0.015;). FeNO values also decreased from 56 
ppb (10-189) to 43 ppb (10-121) (p=0.020; Figure 2).
Table I. Suggested omalizumab dosage.  
      Body weight (kg)
  20-25 25-30 30-40 40-50 50-60 60-70 70-80 80-90 90-125 125-150
Baseline  ≥30-100   75   75   75 150 150 150 150 150 300 300
  IgEs 100-200 150 150 150 300 300 300 300 300 450 600
  (UI/ml) 200-300 150 150 225 300 300 450 450 450 600 
 300-400 225 225 300 450 450 450 600 600 
 400-500 225 300 450 450 600 600 
 500-600 300 300 450 600 600 
 600-700 300  450 600                  Administration every 2 weeks
 ≥800-1100 
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Regarding asthmatic symptomatology, the 
evaluation of Asthma Control test showed a sig-
nificant improvement, from 18 (10-20) to 23 (21-
25) (p=0.003; Figure 3). Also, FEV1 improved, 
though not in a statistically significant way 
(p=0.236; Figure 4).
Blood tests showed increased total serum 
Ig-E from 225 kU/l (36-698) to 747 kU/l (353-
2783; p=0.003). A reduction in eosinophils was 
also observed from 8.5 (3.7-14.9) to 4.9 (2.3-12.7; 
p=0.074), although the decrease was not statisti-
cally significant.
The pharmacological treatment administered 
to the patients before and after the utilization of 
omalizumab is reported in Table III. A reduced in-
take of drugs was observed in all patients. During 
treatment with omalizumab, 2 patients out of 11 
(18.2%) decided to discontinue all other pharmaco-
logical therapy and 6 (54.5%) reduced the number 
of drugs used. Only 3 (27.3%) continued their usual 
pharmacological therapy. None of the participants 
resorted to emergency drugs (SABA, antihista-
minics and topical nasal corticosteroids).
No adverse effects were reported in connec-
tion with the administration of omalizumab.
Discussion
The results of our study show that in patients 
affected by bronchial asthma and allergic rhini-
tis, the treatment of asthma with omalizumab has 
very positive effects also on rhinitis-related symp-
toms. All symptoms improved and nasal turbinate 
hypertrophy was completely resolved in most pa-
tients. Even FeNO levels (sign of upper and lower 
airways inflammation) decreased significantly. 
The efficacy of the therapy was confirmed by the 
reduced intake of symptomatic drugs by the pa-
tients.
Omalizumab is a humanized mouse-derived 
monoclonal antibody weighing approximately 
149 kDa, which binds Ig-E in the part of the mol-
ecule, which connects to FCεRI membrane re-
ceptors of plasma cells, mast cells, basophils and 
eosinophils. This prevents binding between Ig-E 
and effector cells and subsequent phenomena (cell 
activation, the release of mediators responsible 
for the allergic response) triggered by the bond 
between Ig-E and the allergen. In addition to this, 
omalizumab determines a downregulation of Ig-E 
production by B lymphocytes14-16 and of FCεRI 
production by mast cells and basophils. The in-
hibition of FCεRI production is also thought to 
concern dendritic cells, which are involved in the 
initial allergen sensitization, capturing and pro-
cessing allergens and then presenting them to the 
lymphocytes T17,18. Therapy with omalizumab 
is thus potentially efficacious in all pathologies 
whose pathogenesis involves a bond between 
IgEs and effector cells. 
During this study, we assessed the effect of 
anti-IgE monoclonal antibody therapy on allergic 
rhinopathy, accompanied by bronchial asthma. 
Figure 1. Visual Analogue 
Scale (VAS) results.
Table II. Scores for individual symptoms before (T0) and 
after (T1) treatment with omalizumab. Values are expressed 
as a median (range).  
SYMPTOM T0 T1    p
Nasal obstruction 7 (3-10) 3 (2-4)  =0.005
Rhinorrhea 6 (2-8) 3 (0-4) =0.007
Sneezing 5 (2-8) 2 (0-4) <0.003
Itching 3 (0-6) 2 (0-4) =0.041
Tearing 0 (0-10) 0 (0-6) =0.067
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Figure 2. FeNO results.
Figure 3. Asthma con-
trol test results.
Figure 4. FEV1 results.
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This treatment significantly reduced rhinitis-re-
lated symptomatology. The positive effect of treat-
ment with omalizumab was confirmed by the de-
crease in values obtained in the Visual Analogue 
Scale (VAS), both for the mean group value (VAS 
T1=3.3 vs. VAS T0=5.8), and on the values of indi-
vidual patients. All patients reported a significant 
improvement in their general state of health, with 
an evident enhancement of their quality of life. 
The symptoms typically characterizing allergic 
rhinitis as nasal obstruction, rhinorrhea, sneezing, 
itching and tearing, showed improvement, with a 
reduction of initial VAS values. The most severe 
symptom presented by patients at the beginning of 
the study was nasal obstruction (mean VAS=6.27 
with a range of 3-10); this was partly because these 
patients had been referred to the Rhinoallergology 
Day Hospital. At the end of treatment, the symp-
tom was reduced, as confirmed by the mean VAS 
score of 2.9. An improvement was also observed 
in respect of other symptoms, although with a 
very slight effect on tearing, even if this symptom 
was not greatly expressed by our patients. The im-
provement in symptoms was also confirmed by 
nasal endoscopy. Endoscopy was performed at the 
end of the treatment period and it showed an im-
proved state of the nasal mucosa, with a significant 
reduction in the volume of turbinates and mucous 
secretion in the nasal cavities. This improvement 
could not be related to the fact that the trial was 
conducted outside the pollen season, because all 
of our patients were sensitized to perennial aller-
gens (animal hair, dermatophagoides pt, dermato-
phagoides f.). 
Omalizumab also had a good effect on the 
symptoms related to bronchial asthma. All sub-
jects obtained a higher score in the Asthma Con-
trol Test, demonstrating a better control of the 
disease (ACT T1=16.8 vs. ACT T0=22.7). This was 
confirmed both by increased FEV1 values, which 
reflects pulmonary respiratory function, and low-
er FeNO values, which is a very reliable indicator 
of eosinophilic airway inflammation14. In fact the 
persistence of high FeNO values (normal values 
10-25 ppb) despite glucocorticoid therapy, suggests 
a resistance of inflammation to therapy, while val-
ues distributed in the normal range evidently re-
flect a positive response to treatment15. Our study 
did not find a statistically significant correlation 
between FEV1 and FeNO values, in agree with 
previous results reported in the literature14. An-
alyzing the values of the systemic inflammation, 
which occurs during allergic rhinopathy, we ob-
served a significant depletion of serum eosinophils 
following treatment with the anti Ig-E monoclonal 
antibody. This finding is consistent with those of 
other studies about the effect of omalizumab on the 
eosinophil count16. The reduction of eosinophilia in 
peripheral blood reflects omalizumab anti-inflam-
matory effect17, which correlates positively with 
reduced FeNO values, once again confirming that 
fractional exhaled nitric oxide is a very reliable in-
dicator of eosinophilic inflammation15.
Most of the literature on the use of omalizum-
ab concerns the therapy of bronchial asthma. A 
recent Cochrane review19 showed that in patients 
affected by severe asthma being treated with cor-
ticosteroids, this antibody is effective in prevent-
ing asthma attacks, reducing hospitalization and 
limiting the use of symptomatic drugs. Omali-
zumab was also used with encouraging but not yet 
conclusive results in the treatment of some other 
Ig-E related pathologies, including chronic urti-
caria, anaphylaxis, food allergy, atopic dermatitis 
and Allergic bronchopulmonary aspergillosis20. 
Treatment with omalizumab was also tested on 
patients affected by allergic rhinitis. In addition to 
a number of case series, two controlled trials21,22 
were published on patients affected by seasonal 
forms, in whom an improvement of symptoms 
and a lower recourse to symptomatic drugs was 
observed. Another trial23 assessed the effects of 
Table III. Therapy used by patients treated at T
0
 and T1
Legend: ICS, Inhaled Corticosteroids; Oral CS, Oral 
Corticosteroids; SABA, short-acting β2 agonists; Antileuk, 
Leukotriene Inhibitors; LABA, long-acting β2 agonists; SLIT, 
Sublingual Specific ImmunoTherapy.
Patients T0  T1 
Pt. 1 ICS+Antileuk+orali CS ICS+Antileuk
Pt. 2 LABA+ICS+Antileuk
 Emergency SABA ICS+Antileuk
Pt. 3 ICS+Antileuk ICS+Antileuk
Pt. 4 LABA+Antihistaminic No therapy
 Emergency SABA 
Pt. 5 LABA+Antileuk+SLIT
 SABA in emergenza SLIT
Pt. 6 LABA+Antileuk+SLIT
 Emergency SABA SLIT
Pt. 7 LABA+Antileuk+SLIT
 Emergency SABA  SLIT
Pt. 8 LABA+Antileuk+SLIT LABA+
 Emergency SABA Antileuk+
  SLIT
Pt. 9 ICS+Antileuk+oral  CS  No therapy
Pt. 10 ICS ICS
Pt. 11 ICS+ Antileuk+oral CS 
 Emergency SABA  ICS
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the association between omalizumab and specific 
immunotherapy and observed a quicker attenua-
tion of symptoms. In spite of these encouraging 
data, however, the indications for this relatively 
expensive therapy, have to be yet specified ac-
cording to patient and rhinitis characteristics, as 
well as optimal dose and mode of administration. 
In our study omalizumab was administered at 
the dose prescribed for bronchial asthma with ex-
cellent results on the symptomatology of rhinitis. 
The dose influences the cost of therapy but even 
efficacy, because the neutralization of circulating 
Ig-E depends on the serum concentration of omal-
izumab. In one of the two controlled trials, the au-
thors tested different dosages. The improvement 
of symptoms was found to be dose-dependent 
and was optimal when the monoclonal antibody 
reached a serum concentration 15 times greater 
than baseline Ig-E concentration. It should also be 
observed that the ratio between the concentration 
reached by omalizumab and that of Ig-E, is influ-
enced by serum Ig-E levels, which vary greatly. 
In AIFA’s guidelines, an exclusion criterion for 
the treatment of bronchial asthma with omali-
zumab was particularly low or high Ig-E levels. 
The pharmacokinetic properties of omalizumab 
must also be considered: following subcutaneous 
administration, the serum reaches a plateau in 7-8 
days and the half-life of the antibody is about 26 
days. 
Our findings showed increased total serum 
Ig-E amount following treatment with omalizum-
ab, from 2 up to 10 times baseline values. This 
seems to contradict what someone might expect 
following the administration of an anti Ig-E anti-
body. Our data agree with those of other studies on 
this issue. The laboratory method used to measure 
Ig-E (total and specific) does not distinguish free 
molecules from molecules binding to the anti Ig-E 
antibody or to the effector cells (mastocytes and 
basophils)24. Hamilton et al24 have shown a good 
correlation between free serum Ig-E and total se-
rum Ig-E before the beginning of treatment with 
omalizumab, while these two values are no longer 
correlated after treatment. The Ig-E/omalizumab 
complex has a longer plasma half-life than that of 
unbound Ig-E25. This feature determines positive 
effects. The fragment of Ig-E bound to omalizum-
ab and which binds the antigen (Fab) is still free 
and may bind allergens, behaving like a competing 
antagonist of the Ig-E bound to the effector cells14. 
For this reason the level of total and specific Ig-E 
cannot be used to monitor the effect of treatment 
with omalizumab in daily clinical practice. 
The main side effects reported in the literature 
were a local reaction at the point of injection, dif-
fuse urticarial rashes and anaphylaxis. Omalizum-
ab was well tolerated by all patients in this study, 
and no adverse events were reported. In particular, 
no reactions were observed at the point of injection 
at the time of administration or any time later. In 
2007, the omalizumab Joint Task Force (OJTF) rec-
ommended that the administration of omalizumab 
might be preceded by informed consent, adequate 
information/education on anaphylaxis, the avail-
ability of an adrenaline auto-injector, physical ex-
amination, and the observation of 30 minutes after 
the first two shots and two hours after the follow-
ing injections. Our trial was a preliminary study 
conducted in a single center. Its limitations derive 
from the small number of patients and the absence 
of a control group. At present, the Italian Drug Au-
thority’s indications for the use of omalizumab are 
indeed confined to the treatment of patients affect-
ed by bronchial asthma and resistant to normal an-
ti-asthmatic drugs. 
Conclusions
Our data suggest that patients treated with omal-
izumab presented a significant improvement of rhi-
nitis symptoms and a considerable decrease in nasal 
and bronchial mucosa inflammation. Our data also 
confirm that the level of total Ig-E cannot be used 
as an immunity parameter to assess the clinical ef-
ficacy of treatment with omalizumab. In the future, 
the role of omalizumab in the treatment of rhinitis 
patients will have to be assessed by means of multi-
centric controlled prospective studies. 
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